COVID-19 Clinical Trial Pipeline Advances With 180+ Companies and 200+ Therapies

The report provides global coverage of the COVID-19 pipeline landscape and evaluates major companies and therapies under development. Key therapies include Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.

Coverage- Global

COVID-19 Companies- Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.

Conclusion

The COVID-19 clinical trial pipeline continues to evolve, supported by extensive research across antiviral therapies, monoclonal antibodies, vaccines, peptides, immune-based approaches, and other innovative modalities. With more than 180 companies and 200 pipeline therapies, the development landscape encompasses candidates from discovery through Phase III. Emerging therapies such as VYD-2311, ibuzatrelvir, ENTVAX002, ALG-097558, RBM001, MDX2301, and PA-001 demonstrate the diversity of approaches being explored. Continued clinical research, technological innovation, and evaluation of emerging SARS-CoV-2 variants are expected to remain important areas of focus for COVID-19 therapeutic development globally.